|
WO2020225196A1
|
|
Anti-cd19 therapy in patients having a limited number of nk cells
|
|
TW202041535A
|
|
Antibodies targeting c5ar
|
|
WO2020187718A1
|
|
Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
|
|
WO2020120730A1
|
|
Antibody formulations
|
|
WO2020115115A1
|
|
Multispecific antigen-binding molecules
|
|
EP3793596A1
|
|
Antibodies targeting glycoprotein vi
|
|
TW201919698A
|
|
Treatment of atopic dermatitis
|
|
EP3668898A1
|
|
Humanized antibodies for cd3
|
|
CN110799532A
|
|
Canine antibody library
|
|
CN110678201A
|
|
Therapeutic modalities for combination therapy of anti-CD 19 antibody and Venetork
|
|
EP3538552A1
|
|
Fab molecules with a rodent hinge region and a non-rodent ch1 region
|
|
CN109890418A
|
|
The combination and application thereof of anti-CD 19 antibodies and BCL-2 inhibitor
|
|
AU2017289085A1
|
|
Anti-CD19 antibody formulations
|
|
MX2018014702A
|
|
Methods for predicting therapeutic benefit of anti-cd19 therapy in patients.
|
|
EP3423578A1
|
|
Polypeptide library
|
|
AU2017226960A1
|
|
Clinical assessment of M-protein response in multiple myeloma
|
|
MA43088A1
|
|
Anti-il-17c antibodies
|
|
WO2017125601A1
|
|
Anti-bsep-specific antibodies
|
|
CA3000779A1
|
|
Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
|
|
WO2017032679A1
|
|
Combinations and uses thereof
|
